Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT07621601Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2026
- Primary completion
- Dec 2030
01
Overview
A Phase 3 trial of risvutatug rezetecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hansoh Pharmaceutical Group. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07621601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621601.